Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 16/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinapril SCHEMBL7421784 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL4359590 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL153436 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29381792 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29357257 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL41404 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL678447 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL11294979 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL9094436 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL19361887 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| CN-102698245-A | Antihypertensive drug of quinapril hydrochloride and rose oil nanoemulsion | UNIV NORTHWEST A&F | 2012-10-03 | — | — | CN | disclosed |
| CN-102109502-A | Method for simultaneously detecting main component contents of quinapril hydrochloride and hydrochlorothiazide composition | YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO LTD | 2011-06-29 | — | — | CN | disclosed |
| CN-100496604-C | Storage-stable and biologically stable formulations of ACE inhibitors and methods of making the same | SIGMAPHARM INC (US) | 2009-06-10 | — | — | CN | disclosed |
| CN-1758921-A | Storage-stable and bio-stable formulations of ACE inhibitors, and methods for preparation thereof | SIGMAPHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-0992495-B1 | PROCESS FOR OBTAINING QUINAPRYL HYDROCHLORIDE AND SOLVATES USEFUL FOR ISOLATING AND PURIFYING QUINAPRYL HYDROCHLORIDE | ESTEVE QUIMICA SA (ES) | 2004-02-04 | — | — | EP | disclosed |
| US-6617457-B1 | Hydrogenolysis of the benzyl ester of quinapril in an alcoholic solvent, with hydrochloric acid and hydrogenation; removal of the solvent; addition of toluene to precipitate the product as a solvate | ESTEVE QUIMICA, S.A. (ES) | 2003-09-09 | — | — | US | disclosed |
| CN-1048546-A | Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine | MERCK & CO INC (US) | 1991-01-16 | — | — | CN | disclosed |